Ophtesic (Anhydrous Lidocaine Hydrochloride)

Lidocaine hydrochloride blocks voltage‑gated sodium channels on sensory nerve endings of the eye. By preventing sodium influx, it stops the generation and propagation of nerve impulses, resulting in rapid, reversible loss of sensation in the ocular surface.

The appropriate dose of Ophtesic is determined by the prescribing clinician based on the specific procedure, patient age, and clinical setting. The prescriber will specify the volume and frequency of application required for each individual case.

Safety data for Ophtesic in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare professional.

To order Ophtesic, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details, and import documentation.

Ophtesic contains lidocaine, an amide‑type local anesthetic with a rapid onset and short duration, making it suitable for brief procedures. Compared with ester‑type agents such as proparacaine, lidocaine generally offers a slightly longer duration of anesthesia but a similar safety profile when used correctly.

Ophtesic should be stored at room temperature, below 25 °C, in its original packaging. Protect the container from direct sunlight, moisture, and extreme temperature fluctuations to maintain product stability.

Ophtesic is applied topically to the ocular surface as a drop or a small amount of solution, as directed by the clinician. The eye should be gently closed after administration to allow adequate absorption, and contact lenses should be removed beforehand.

Serious risks, though rare, include corneal epithelial toxicity, severe allergic reactions such as contact dermatitis, and, in cases of significant systemic absorption, signs of lidocaine toxicity like cardiac arrhythmias or central nervous system effects.

Ophtesic should be avoided in individuals with known hypersensitivity to lidocaine or other amide local anesthetics, in eyes with active infection or severe inflammation unless specifically indicated, and in patients with certain cardiac conduction disorders where systemic absorption could pose a risk.